» Articles » PMID: 29861492

Prioritization of Variants Detected by Next Generation Sequencing According to the Mutation Tolerance and Mutational Architecture of the Corresponding Genes

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Jun 5
PMID 29861492
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The biggest challenge geneticists face when applying next-generation sequencing technology to the diagnosis of rare diseases is determining which rare variants, from the dozens or hundreds detected, are potentially implicated in the patient's phenotype. Thus, variant prioritization is an essential step in the process of rare disease diagnosis. In addition to conducting the usual in-silico analyses to predict variant pathogenicity (based on nucleotide/amino-acid conservation and the differences between the physicochemical features of the amino-acid change), three important concepts should be borne in mind. The first is the "mutation tolerance" of the genes in which variants are located. This describes the susceptibility of a given gene to any functional mutation and depends on the strength of purifying selection acting against it. The second is the "mutational architecture" of each gene. This describes the type and location of mutations previously identified in the gene, and their association with different phenotypes or degrees of severity. The third is the mode of inheritance (inherited vs. de novo) of the variants detected. Here, we discuss the importance of each of these concepts for variant prioritization in the diagnosis of rare diseases. Using real data, we show how genes, rather than variants, can be prioritized by calculating a gene-specific mutation tolerance score. We also illustrate the influence of mutational architecture on variant prioritization using five paradigmatic examples. Finally, we discuss the importance of familial variant analysis as final step in variant prioritization.

Citing Articles

Trio-whole exome sequencing reveals the importance of de novo variants in children with intellectual disability and developmental delay.

Li C, Wang Y, Zeng C, Huang B, Chen Y, Xue C Sci Rep. 2024; 14(1):27590.

PMID: 39528574 PMC: 11555314. DOI: 10.1038/s41598-024-79431-x.


Implementing Whole Genome Sequencing (WGS) in Clinical Practice: Advantages, Challenges, and Future Perspectives.

Brlek P, Bulic L, Bracic M, Projic P, Skaro V, Shah N Cells. 2024; 13(6.

PMID: 38534348 PMC: 10969765. DOI: 10.3390/cells13060504.


Whole-Genome Profile of Greek Patients with Teratozοοspermia: Identification of Candidate Variants and Genes.

Kyrgiafini M, Giannoulis T, Chatziparasidou A, Christoforidis N, Mamuris Z Genes (Basel). 2022; 13(9).

PMID: 36140773 PMC: 9498395. DOI: 10.3390/genes13091606.


Validation of New Gene Variant Classification Methods: a Field-Test in Diagnostic Cardiogenetics.

Alimohamed M, Westers H, Vos Y, van der Velde K, Sijmons R, van der Zwaag P Front Genet. 2022; 13:824510.

PMID: 35299955 PMC: 8921548. DOI: 10.3389/fgene.2022.824510.


Intellectual disability genomics: current state, pitfalls and future challenges.

Maia N, Nabais Sa M, Melo-Pires M, de Brouwer A, Jorge P BMC Genomics. 2021; 22(1):909.

PMID: 34930158 PMC: 8686650. DOI: 10.1186/s12864-021-08227-4.


References
1.
Kalscheuer V, Feenstra I, van Ravenswaaij-Arts C, Smeets D, Menzel C, Ullmann R . Disruption of the TCF4 gene in a girl with mental retardation but without the classical Pitt-Hopkins syndrome. Am J Med Genet A. 2008; 146A(16):2053-9. DOI: 10.1002/ajmg.a.32419. View

2.
Cao H, Hegele R . Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 1999; 9(1):109-12. DOI: 10.1093/hmg/9.1.109. View

3.
Petrovski S, Wang Q, Heinzen E, Allen A, Goldstein D . Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 2013; 9(8):e1003709. PMC: 3749936. DOI: 10.1371/journal.pgen.1003709. View

4.
Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, Moller R . Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology. 2013; 81(19):1697-703. PMC: 3812107. DOI: 10.1212/01.wnl.0000435296.72400.a1. View

5.
ORoak B, Deriziotis P, Lee C, Vives L, Schwartz J, Girirajan S . Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011; 43(6):585-9. PMC: 3115696. DOI: 10.1038/ng.835. View